MedTrace Logo

Senolytics for Secondary Progressive MS

NCT07270120 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-08

No results posted yet for this study

Summary

This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.

Conditions

  • Multiple Sclerosis (MS) Secondary Progressive

Interventions

DRUG

Dasatinib and quercetin

Participants will receive 100 mg of dasatinib and 1250 mg of quercetin orally once a day for 2 days every 2 weeks over 12 consecutive weeks

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-15
Primary Completion
2027-01-15
Completion
2028-01-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07270120 on ClinicalTrials.gov